Cutaneous Ewing’s sarcoma secondary to chemotherapy given for testis tumor: Case report

Serhat Tanık a, Kürşad Zengin a,⁎, Sebahattin Albayrak a, Recep Eryılmaz b, Deniz Yılmaz c, Necip Pirinçci b

a Bozok University, Faculty of Medicine, Department of Urology, Yozgat, Turkey
b Yuzuncu Yil University, Faculty of Medicine, Department of Urology, Van, Turkey
c Yuzuncu Yil University, Faculty of Medicine, Department of Pathology, Turkey

A R T I C L E   I N F O

Article history:
Received 29 January 2014
Received in revised form 2 July 2014
Accepted 7 October 2014
Available online 22 October 2014

Keywords:
Secondary tumor
Chemotherapy
Ewing’s sarcoma

A B S T R A C T

INTRODUCTION: Testicular cancer has high cure rates, especially after the adjuvant use of chemotherapy. Secondary tumors may develop months and years after the primary tumor. We aimed to report a case of cutaneous Ewing’s sarcoma at the site of surgery 3 years after BEP chemotherapy.

PRESENTATION OF CASE: 21 year old male underwent radical orchiectomy in 2008. After one year surgical site complaints brought him to same hospital. A limited surgical resection was made. As his complaints continued he applied to our clinic. We resected the lesion with a 5 cm safety margin with the light of previous medical history. Pathology revealed cutaneous Ewing’s sarcoma, and patient received VACD-IE chemotherapy. He is free of recurrence till now.

DISCUSSION: Chemotherapy may cause secondary cancer especially in long term. In this case secondary tumor is diagnosed three years after surgery. Patient underwent therapeutic surgery and received chemotherapy (VACD-IE) for secondary Ewing’s sarcoma. Early diagnosis and definitive treatment provide recurrence free survival in the patient.

CONCLUSION: Secondary tumors can emerge months or years after primary tumor therapies, and are not related with the primary tumors. Any lesion or sign should be investigated carefully. Early diagnosis and correct treatment could prevent dramatic results.

⁎ Corresponding author: Bozok Universitesi Uygulama ve Araştırma Hastanesi, Uroloji Ana Bilim Dali, Adnan Menderes Bulvari, No: 150, Yozgat, Turkey.
Tel.: +90 505 474 24 70; fax: +90 354 214 06 12.
E-mail addresses: tanikserhat@gmail.com (S. Tanık), kursadzengin@gmail.com (K. Zengin), salbayrak77@hotmail.com (S. Albayrak), baveryilmaz@hotmail.com (R. Eryılmaz), drdeniz27@mynet.com (D. Yılmaz), necippirincc@mynet.com (N. Pirinçci).

We aimed to report a case with cutaneous Ewing sarcoma at the site of surgery 3 years after BEP chemotherapy. To our knowledge it is the first case of secondary Ewing’s sarcoma after chemotherapy of testicular cancer.

2. Presentation of case

21 year old male patient underwent radical orchiectomy for testicular mass in a state hospital in 2008. The patient had no previous story of familial testicular cancer and other malignancies. Pathology report revealed mixed germ cell tumor, and patient received 2 cycles of BEP chemotherapy in the same hospital. The patient presented a year later with discharge and inflammation at the site of the wound. A limited surgical resection was performed and pathology revealed atypical cellular differentiation and foreign body reaction. Patient’s complaints continued after this operation and referred to our clinic after 12 months in 2011 (Fig. 1). Laboratory investigations including complete blood count, blood urea nitrogen, creatinine, alpha feto protein, β human chorionic gonadotropin, carcinoembryogenic antigen, and lactate dehydrogenase levels were in normal ranges. Ultrasound reported that the lesion was limited to skin and subcutaneous tissue. We resected...
the lesion with a 5 cm safety margin with the light of previous medical history. Pathology revealed cutaneous Ewing sarcoma with negative margins (Fig. 2). The patient had received vincristine, actinomycin D, cyclophosphamide, doxorubicin, ifosfamide and etoposide (VACD-IE) chemotherapy regime and is free of recurrence till September 2013.

3. Discussion

Secondary tumors can emerge months or years after primary tumor therapies, and are not related with the primary tumors. The chemotherapeutics used for the primary tumor, inactivate the cancer cells by disrupting cellular division, and may also affect normal cells in many ways. Secondary tumors have different characteristics than primary tumors even in the same region. Furthermore primary therapy regimes could restrict secondary therapy, and reduce survival.4,5

Travis et al. studied 40,576 testicular cancer patients with at least one year of survival. They reported 2200 secondary solid tumors in these patients. This study demonstrated the increased incidence in secondary tumors such as leukemia and some solid tumors (lung, thyroid, esophagus, stomach, pancreas, colon, rectum, kidney, bladder, connective tissue cancers and malignant mesothelioma). They also reported that younger patients at the time of diagnosis might experience high risk of secondary tumors as they get older.6

A similar study was conducted in Holland, reported subdiaphragmatic radiotherapy increases the risk of secondary tumors. The study also demonstrated a 4% increased risk in radiotherapy and 1.5% increased risk in chemotherapy for secondary tumors in 20 years of follow-up.7

Secondary cancers can occur following treatment with chemotherapy. Cisplatin as an alkylation agent and etoposide as a Topoisomerase-II inhibitor have been shown to be the cause of secondary cancers.8 It was also shown that etoposide and cisplatin had synergistic effects for secondary leukemia when used together for chemotherapy.9

The standard chemotherapy of Ewing's sarcoma has been evolved since the first independent reports of Sutow, and Pinkel.10,11 In 1974 Rosen et al, reported first results of radiotherapy with four drug regimen consisting of vincristine, actinomycin D, cyclophosphamide, and doxorubicin (VACD) leading to long term survival.12 The Pediatric Oncology Group–Children’s Cancer Group (POG–CCG) reported a comparative study of VACD versus VACD plus etoposide and ifosfamide (IE). VACD-IE group achieved a 5 year event-free survival (EFS) rate of 69% versus 54% in the VACD group.13

Chemotherapy may cause secondary cancer especially in long term. In this case secondary tumor is diagnosed three years after surgery. Patient underwent therapeutic surgery and received chemotherapy (VACD-IE) for secondary Ewing’s sarcoma. Early diagnosis and definitive treatment provide recurrence free survival in the patient.

4. Conclusion

Secondary tumors may arise years after chemotherapy. Any lesion or sign should be investigated carefully. Early diagnosis and correct treatment could prevent dramatic results.

Conflict of interest

We certify that there is no conflict of interest with any financial organization regarding the material discussed in the article.

Funding

None.

Ethical approval

Written informed consent was obtained from the patient for publication of this case report and case series and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contributions

Serhat Tanik performed the orchietomy. Kursad Zengin and Sebahattin Albayrak wrote the manuscript. Necip Pirincci and Recep Eryilmaz performed the last operation and chemotherapy. Deniz Yilmaz performed the pathological evaluation.

References

1. Hayes-Lattin B, Nichols CR. Testicular cancer: a prototypic tumor of young adults. Semin Oncol 2009;36(October (5)):432–8.
2. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008;299(6):672–84.
3. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, et al. Risk of second survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.
4. Robinson E, Neugut AI. Clinical aspects of multiple primary neoplasms. Cancer Detect Prev 1989;13:287–92.
5. Claj N, te Riele H. Micrastellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res 1999;246:1–10.
6. Travis LB, Fossa SD, Schoenfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354–65.
7. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370–8.
8. Felix CA. Chemotherapy-related second cancers. In: Neugut AI, Meadows AT, Robinson E, editors. Multiple primary cancers. Philadelphia, PA: Lippincott Williams and Wilkins; 1999. p. 137–64.
9. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994;83:2780–6.
10. Sutow WW, Sullivan MP. Cyclophosphamide therapy in children with Ewing’s sarcoma. Cancer Chemother Rep 1962;23:55–60.
11. Pinkel D. Cyclophosphamide in children with cancer. Cancer 1962;15:42–9.
12. Rosen G, Wollner N, Tan C, Wu SJ, Hajdu SI, Cham W, et al. Proceedings: disease-free survival in children with Ewing’s sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 1974;33:384–93.
13. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694–701.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.